Summary
For the purpose of observing the therapeutic benefit of protease inhibitors for progressive muscular dystrophy, a large quantity of doses of leupeptin of 10 mg/kg/day and 50 mg/kg/day were administered i.p. to male chickens afflicted with hereditary muscular dystrophy (line 413) for 4 months starting on the 7th day ex ovo. No clinical improvement was identified in physical ability as a result of the examination by flip test, and creatine kinase (CK) values. The number of necrotic fibers in the pectoralis superficialis (PS) muscle which is known to be preferentially damaged in dystrophic chicken, did not decrease significantly in the birds treated with 10 mg leupeptin/kg/day (number of necrotic fibers; 47.7/mm2) and 50 mg/kg/day (46.4/mm2) as compared to that of the untreated ones (43.2/mm2). A morphometric analysis of fiber diameter distribution also showed no statistical difference between the treated and untreated birds.
In the second group, 10 mg leupeptin/kg and a combination of leupeptin and bestatin of 10 mg/kg each were injected directly into the left lower half of the PS muscle three times a week for 4 months. Necrotic fibers were still present in the injected site, remote area of the left upper PS muscle treated with leupeptin (52.7/mm2), leupeptin and bestatin (52.2/mm2), and contralateral right upper PS muscle (41.6 and 53.5/mm2, respectively). The number of necrotic fibers in treated muscles was again not significantly different from that in untreated dystrophic ones (39.6/mm2). In fiber diameter analysis, no statistical difference was recognized between the treated and untreated dystrophic muscles.
Similar content being viewed by others
References
Aoyagi T, Miyata S, Nanbo M, Kojima E, Matsuzaki M, Ishizuka M, Takeuchi T, Umezawa H (1969a) Biological activities of leupeptins. J Antibiot 22:558–568
Aoyagi T, Takeuchi T, Matsuzaki A, Kawamura K, Kondo S, Hamada M, Maeda K, Umezawa H (1969b) Leupeptins, new protease inhibitors from actinomycetes. J Antibiot 22:283–286
Barret AJ (1977) Cathepsin D and other carboxyl proteinases. In: Barret AJ (ed) Proteinases in mammalian cells and tissues. North-Holland, Amsterdam, pp 209–248
Bodensteiner JB, Engel AG (1978) Intracellular calcium accumulation in Duchenne dystrophy and other myopathics. A study of 567,000 muscle fibers in 114 biopsies. Neurology (Minneap) 28: 439–446
Bradley WG, Fulthorpe JJ (1978) Studies of sarcolemmal integrity in myopathic muscle. Neurology (Minneap) 28:670–677
Carpenter S, Karpati G (1979) Duchenne muscular dystrophy. Plasma membrane loss initiates muscle cell necrosis unless it is repaired. Brain 102:147–161
Chelmicka-Schorr EE, Arnason BGW, Åström KE, Darzynkiewicz Z (1978) Treatment of mouse muscular dystrophy with the protease inhibitor pepstatin. J Neuropathol Exp Neurol 37: 263–268
Dubowitz V, Brooke MH (1973) Muscle biopsy. — A modern approach. Saunders, London
Enomoto A, Bradley WG (1977) Therapeutic trials in muscular dystrophy. III. Studies of microbial proteinase inhibitors in murine dystrophy. Arch Neurol 34:771–773
Hashida S, Towatari T, Kominami E, Katunuma N (1980) Inhibitions by E64 derivatives of rat liver cathepsin B and cathepsin L in vitro and in vivo. J Biochem (Tokyo) 88:1805–1811
Hudecki MS, Pollina CM, Bhargava AK, Hudecki RS, Heffner RR (1979) Delayed functional disability in dystrophic chickens receiving chemotherapy. Muscle Nerve 2:57–67
Hudecki MS, Pollina CM, Heffner RR (1981) In vivo effects of protease inhibitors on chickens with hereditary muscular dystrophy. J Clin Invest 67:969–974
Ionasescu V, Ionasescu R, Witte D, Feld R, Cancilla P, Kaeding L, Kraus L, Stern L (1980) Altered protein synthesis and creatine kinase in breast muscle cell culture from dystrophic chick embryos. Corrective influence of leupeptin, pepstatin and diphenylhydantoin. J Neurol Sci 46:157–168
Ishiura S (1981) Calcium-dependent proteolysis in living cells. Life Sci 29:1079–1087
Ishiura S, Nonaka I, Sugita H (1981) Suppression of calcium-induced removal of the Z-line by a thiol-protease inhibitor, E-64-c. J Biochem (Tokyo) 90:283–285
Kar NC, Pearson CM (1980) Elevated activity of a neutral proteinase in human muscular dystrophy. Biochem Med 24:238–243
Katunuma N, Hanada K (1982) New synthetic substrate for cathepsins B and L. J Biochem (Tokyo) (in press)
Libby P, Goldberg AL (1978) Leupeptin, a protease inhibitor, decreases degradation in normal and diseased muscles. Science 199:534–536
Libelius R, Jirmanová I, Lundquist I, Thesleff S, Barnard EA (1979) T-tubule endocytosis in dystrophic chicken muscle and its relation to muscle fiber degeneration. Acta Neuropathol (Berl) 48: 31–38
Lowry OM, Rosenbrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the phenol reagent. J Biol Chem 193:265–275
Matsushita H, Tuji S (1981) Therapeutic effect of leupeptin and bestatin in various enzyme levels in dystrophic mouse. In: Umezawa H (ed) Annual research report of leupeptin derived from bacterial metabolites, Ministry of Health and Welfare, Tokyo, Japan, pp 55–61
McGowan EB, Shafiq SA, Stracher A (1976) Delayed degeneration of dystrophic and normal muscle cell cultures treated with pepstatin, leupeptin, and antipain. Exp Neurol 50:649–657
Mendell JR, Higgins R, Sahenk Z, Cosmos E (1979) Relevance of genetic animal models of muscular dystrophy to human muscular dystrophies. Ann NY Acad Sci 317:409–430
Mokri B, Engel AG (1975) Duchenne dystrophy. Electron-microscopic findings pointing to a basic or early abnormality in the plasma membrane of the muscle fiber. Neurology (Minneap) 25: 1111–1120
Nonaka I, Sugita H (1981) Intracytoplasmic vacuoles in αW fibers of dystrophic chicken muscle; probable early pathologic event initiates massive fiber necrosis. Acta Neuropathol (Berl) 55: 173–181
Nonaka I, Sunohara N, Sugita H, Ishiura S (1979) A histological and histochemical study of chick dystrophic skeletal muscle. Neurol Med (Tokyo) 11:259–269
Nonaka I, Takagi A, Ishiura S, Murakami H, Sugita H (1980) Therapeutic effect of leupeptin in chicken muscular dystrophy. In: Umezawa H (ed) Annual research report of leupeptin derived from bacterial metabolites. Ministry of Health and Walfare, Tokyo, Japan, pp 55–59
Oberc MA, Engel WK (1977) Ultrastructural localization of calcium in normal and abnormal skeletal muscle. Lab Invest 36:566–577
Schmalbruch H (1975) Segmental fibre breakdown and defects of the plasmalemma in diseased human muscles. Acta Neuropathol (Berl) 33:129–141
Sher JH, Stracher A, Shafiq SA, Hardy-Stashin J (1981) Successful treatment of murine muscular dystrophy with the proteinase inhibitor leupeptin. Proc Natl Acad Sci USA 78:7742–7744
Stracher A, McGowan EB, Shafiq SA (1978) Muscular dystrophy: Inhibition of degeneration in vivo with protease inhibitors. Science 200:50–51
Stracher A, Sher J, Shafiq S (1980) Leupeptin treatment of mice with hereditary muscular dystrophy. In: Angelini C, Danieli GA, Fontanari D (eds) Muscular dystrophy research. Advances and new trends. Excerpta Medica. Amsterdam, p 305
Sugita H, Ishiura S, Suzuki K, Imahori K (1980a) Ca-activated neutral protease and its inhibitors; in vitro effect on intact myofibrils. Muscle Nerve 3:335–339
Sugita H, Ishiura S, Suzuki K, Imahori K (1980b) Inhibition of epoxide derivatives on chicken calcium-activated neutral protease (CANP) in vitro and in vivo. J Biochem (Tokyo) 87:339–341
Sugita H, Kimura M, Tarumoto Y, Tamai M, Hanada K, Ishiura S, Nonaka I, Ohzeki M, Imahori K (1982) In vivo administration of a thiol protease inhibitor, E-64-c to hereditary dystrophic chicken. Muscle Nerve (in press)
Sugita H, Toyokura Y (1976) Alteration of troponin subunits in progressive muscular dystrophy (DMP). II. Mechanism of the alteration of troponin subunits in DMP. Proc Jpn Acad 53: 260–263
Takagi A, Nonaka I, Ishiura S, Murakami H, Sugita H (1980) Experimental therapeutic trial of leupeptin to chickens with muscular dystrophy. In: Umezawa H (ed) Annual research report of leupeptin derived from bacterial metabolites. Ministry of Health and Welfare. Tokyo, Japan, pp 51–53
Tanaka W, Yamashita Y, Minakuchi S, Takayama H, Ishibashi M, Miyazaki H (1981) Developmental research of leupeptin as a therapeutic drug for incurable diseases. In: Umezawa H (ed) Annual research report of leupeptin derived from bacterial metabolites. Ministry of Health and Welfare, Tokyo, Japan, pp 101–112
Wilson BW, Randall WR, Patterson GT, Entrikin RK (1979) Major physiologic and histochemical characteristics of inherited dystrophy of the chicken. Ann NY Acad Sci 317:224–246
Author information
Authors and Affiliations
Additional information
Partly supported by a grant-in-aid for New Drug Development Research from the Ministry of Health and Welfare, Japan
Rights and permissions
About this article
Cite this article
Nonaka, I., Ishiura, S., Takagi, A. et al. Therapeutic trial with protease inhibitor (Leupeptin) in chicken muscular dystrophy. Acta Neuropathol 58, 279–285 (1982). https://doi.org/10.1007/BF00688610
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00688610